Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;14(6):PCC.12br01401.
doi: 10.4088/PCC.12br01401. Epub 2012 Nov 8.

Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases

Yakup Albayrak  1 , Kenji Hashimoto
Affiliations

Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases

Yakup Albayrak et al. Prim Care Companion CNS Disord. 2012.

Abstract

Objective: Tardive dyskinesia (TD) is characterized by involuntary, repetitive, purposeless movements that can affect different parts of the body. Tardive dyskinesia is a well-known side effect of conventional antipsychotics and commonly occurs after several years of treatment. The effective treatment of TD is unclear. Recently, the sigma-1 receptor agonist fluvoxamine was reported to be beneficial for hyperkinetic movement disorders.

Method: We report 5 cases with postpsychotic depressive disorder of schizophrenia and TD. All patients were given fluvoxamine 100 mg/d, and after the second week the dosage of fluvoxamine was increased to 200 mg/d. At the fourth week, patients were assessed in terms of TD and postpsychotic depressive disorder of schizophrenia.

Results: Fluvoxamine was found to be beneficial for TD and postpsychotic depressive disorder of schizophrenia in all patients by the fourth week.

Conclusions: Recently, the sigma-1 receptor agonist fluvoxamine has been considered beneficial for various neuropsychiatric disorders. However, data about the effects of fluvoxamine on hyperkinetic movement disorders are limited. In this report, we attempted to demonstrate the beneficial effects of fluvoxamine on TD, and we suggest that the mechanism of action might be due to sigma-1 agonism. Further detailed, double-blind studies should clarify the potential use of fluvoxamine in the treatment of hyperkinetic movement disorders.

PubMed Disclaimer

References

    1. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999;7(1):70–76. - PubMed
    1. Laporta M, Archambault D, Ross-Chouinard A, et al. Articulatory impairment associated with tardive dyskinesia. J Nerv Ment Dis. 1990;178(10):660–662. - PubMed
    1. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18(3):197–214. - PubMed
    1. Schwartz M, Silver H, Tal I, et al. Tardive dyskinesia in northern Israel: preliminary study. Eur Neurol. 1993;33(3):264–266. - PubMed
    1. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem. 2009;9(3):197–204. - PubMed